<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167683</url>
  </required_header>
  <id_info>
    <org_study_id>P-2019-223</org_study_id>
    <nct_id>NCT04167683</nct_id>
  </id_info>
  <brief_title>Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant</brief_title>
  <official_title>The Effect of Medical Treatment on Muscle Dysfunction and the Prognostic Role of Muscle Dysfunction at Critical Decision Points in Patients With Hematological Diseases Referred to Myeloablative Hematopoietic Stem Cell Transplant (HSCT), to Myeloablative HSCT With a &quot;Reduced Toxicity Conditioning&quot; Regime With Fludarabine and Treosulfane (FluTreo), or to Non-myeloablative HSCT. - A Prospective Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: To investigate the effect of the disease and HSCT on muscle dysfunction and to
      investigate the prognostic role of muscle dysfunction at critical decision points in patients
      with hematological diseases referred to hematopoietic stem cell transplant (HSCT).

      HSCT: Patients diagnosed with malignant hematological diseases who are referred to
      myeloablative HSCT, to a myeloablative &quot;reduced toxicity conditioning&quot; regime with
      Fludarabine and Treosulfane (FluTreo) or to non-myeloablative HSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONAL: Patients diagnosed with malignant hematological diseases undergoing HSCT are faced
      with poor prognosis. The treatment is demanding and associated with severe deconditioning
      potentially leading to worse prognostic outcomes. To what extend patients body composition at
      the point of referral to HSCT, as well as changes in body composition throughout the cancer
      continuum is associated with cancer outcomes is currently not well described, specifically if
      this should be part of standard clinical evaluation in order to optimize therapy-efficacy.
      Recent findings suggest that pathophysiological alterations in skeletal muscle mass and
      function can have significant implications for the risk of disease progression and long term
      prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1 and Cohort 2 Medical treatment complications</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Incidens rate of medical complications (mortality, re-hospitalization, infections, all cause disease relapse, chronic GVHD, return to work)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization duration</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Total number days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Risk of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Risk of mortality from any-cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole body lean mass</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appendicular lean mass</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole body fat percentage</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat mass</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral content</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking capacity</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Maximum 10 meter walking speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lower body physical function</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>30 seconds Sit-To- Stand test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum leg power</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Leg extensor power test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Blood values are registered from the patients hospital record in relation to assessments. C-reactive protein (CRP) and leucocytes are registered as they are inflammation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine and hemoglobin</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Blood values are registered from the patients hospital record in relation to assessments. C-reactive protein (CRP) and leucocytes are registered as they have an influence on muscle strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body fat percentage, fat mass, fat-free mass, muscle mass and bone mass and total body water</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Bioelectrical Impedance Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 Version 3.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychological distress</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity level</measure>
    <time_frame>From baseline to 1 year follow-up</time_frame>
    <description>International Physical Activity Questionnaire (IPAQ) short form</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Patients referred to myeloablative HSCT</arm_group_label>
    <description>These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Patients referred to non myeloablative HSCT</arm_group_label>
    <description>These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Cohort 1 - Patients referred to myeloablative HSCT</arm_group_label>
    <arm_group_label>Cohort 2 - Patients referred to non myeloablative HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with malignant hematological diseases referred to myeloablative HSCT,
        myeloablative RTC-HSCT or non-myeloablative HSCT.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with acute myelogenous leukaemia (AML), acute lymphatic leukaemia
             (ALL), chronic myelomonocytic leukaemia (CMML), myelodysplastic syndrome (MDS),
             chronic lymphatic leukaemia (CLL), malignant lymphomas or multiple myeloma (MM)
             referred to myeloablative HSCT, myeloablative RTC-HSCT or non-myeloablative HSCT at
             the Department of Haematology, Rigshospitalet, Blegdamsvej.

        Exclusion Criteria:

          -  age &lt;18; pregnancy; physical or mental disabilities precluding test of muscle
             function; inability to read and understand Danish
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Christensen, post doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Occupational- and Physiotherapy, Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Christensen, post doc</last_name>
    <phone>0045 22479075</phone>
    <email>jan.christensen.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina HÃ¸gdal, MSc</last_name>
    <phone>0045 35450503</phone>
    <email>nina.hoegdal@region.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jan Christensen</investigator_full_name>
    <investigator_title>post doc</investigator_title>
  </responsible_party>
  <keyword>Muscle mass</keyword>
  <keyword>Muscle strength</keyword>
  <keyword>Complications</keyword>
  <keyword>Patient reported outcomes</keyword>
  <keyword>PRO</keyword>
  <keyword>Physical function</keyword>
  <keyword>hematopoietic stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not provided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

